Pacira BioSciences, Inc.
As of Oct 22, 2026, Pacira BioSciences is in Stage 2, the uptrend phase, now in week 2 (since Oct 12, 2026). It closed at $36.34, at its 52-week high and above its 200-day average, which is rising.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 26 in Drug Manufacturers - Specialty & Generic · #1 of 272 in Health Care
Is PCRX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
PCRX among Drug Manufacturers - Specialty & Generic12th of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
| …12 | PCRX | Stage 2 · wk 2 | 90 | +47.5% |
Pacira BioSciences: quick answers
What stage is Pacira BioSciences in?
As of Oct 22, 2026, Pacira BioSciences (PCRX) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 12, 2026 and is in week 2. What the four stages mean
Is Pacira BioSciences in an uptrend?
Yes. Pacira BioSciences is in a Stage 2 uptrend. It trades 48.6% above its 200-day average, which is rising.
How far is Pacira BioSciences from its 52-week high?
Pacira BioSciences closed at $36.34 on Oct 22, 2026, at its 52-week high. Its 52-week low is $19.16.
How has Pacira BioSciences performed over the past year?
As of Oct 22, 2026, Pacira BioSciences is up 65.0% over the past year and up 48.6% so far in 2026.
Which sector and industry is Pacira BioSciences in?
Pacira BioSciences is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.